background
patient
hematolog
malign
febril
neutropenia
fen
frequent
complic
import
caus
mortal
variou
risk
factor
identifi
sever
infect
neutropen
patient
howev
best
knowledg
defin
whether
chang
risk
febril
neutropenia
accord
season
first
aim
studi
determin
differ
frequenc
febril
neutropen
episod
fne
accord
month
season
second
aim
document
isol
pathogen
well
demograph
clinic
characterist
patient
method
studi
fne
patient
follow
hematolog
malign
june
may
evalu
retrospect
result
although
number
fne
increas
autumn
signific
differ
frequenc
fne
month
p
season
p
isol
pathogen
fne
fne
pathogen
isol
pathogen
gram
neg
bacteria
gram
posit
bacteria
virus
fungi
parasit
frequenc
fen
chang
accord
month
season
also
rel
proport
differ
pathogen
caus
fen
vari
accord
season
febril
neutropenia
fen
common
complic
requir
hospit
caus
mortal
patient
hematolog
cancer
also
febril
episod
prolong
durat
hospit
neutropen
patient
clinic
document
infect
occur
febril
episod
infect
document
patient
fen
caus
endogen
flora
among
circulatori
respiratori
system
infect
common
gram
neg
bacteria
frequent
detect
infecti
agent
gram
posit
bacteria
becam
common
factor
follow
year
due
increas
use
vascular
cathet
prophylact
antibiot
applic
toxic
intestin
chemotherapi
applic
howev
recent
year
rate
gram
neg
bacteria
increas
commonli
seen
gram
posit
bacteria
aureu
coagulas
neg
staphylococcu
cn
streptococcu
speci
gram
neg
bacteria
includ
e
coli
klebsiella
speci
p
aeruginosa
fungal
agent
commonli
candida
aspergillu
also
identifi
caus
fen
sever
neutropenia
prolong
neutropenia
presenc
mucos
type
cancer
acut
leukemia
highrisk
myelodysplast
syndrom
uncontrol
progress
cancer
induct
therapi
applic
intens
chemotherapi
hematopoiet
stem
cell
transplant
presenc
comorbid
disord
requir
hospit
use
central
venou
cathet
use
monoclon
antibodi
poor
perform
statu
advanc
age
risk
factor
defin
fen
develop
best
knowledg
season
month
defin
risk
factor
fen
hematolog
cancer
patient
primari
aim
studi
investig
whether
relationship
frequenc
febril
neutropen
episod
fne
season
hematolog
cancer
patient
second
aim
studi
determin
type
frequenc
pathogen
detect
fne
studi
fne
patient
hematolog
malign
follow
multidisciplinari
hospit
akdeniz
univers
school
medicin
hospit
june
may
evalu
patient
allogen
stem
cell
transplant
includ
studi
avail
medic
file
biolog
result
patient
retrospect
review
accord
asco
guidelin
fever
defin
singl
oral
temperatur
measur
temperatur
sustain
one
hour
period
defin
neutropenia
absolut
neutrophil
count
anc
cellsmm
anc
expect
decreas
cellsmm
next
h
clinic
demograph
data
patient
month
season
fne
note
addit
neutrophil
count
creactiv
protein
crp
level
length
hospit
cultur
result
blood
bodi
specimen
isol
pathogen
detect
foci
infect
antibacteri
antivir
antifung
treatment
review
studi
protocol
approv
institut
ethic
committe
akdeniz
univers
school
medicin
hospit
conduct
accord
principl
declar
helsinki
good
clinic
practic
guidelin
intern
confer
harmon
addit
descript
statist
method
mean
median
standard
deviat
test
use
compar
qualit
data
student
ttest
use
quantit
twogroup
comparison
paramet
normal
distribut
result
evalu
confid
interv
signific
level
p
male
femal
patient
median
length
hospit
stay
day
demograph
characterist
case
present
tabl
fne
occur
given
period
chemotherapyinduc
neutropenia
fne
chemotherapi
regimen
includ
differ
protocol
ten
percent
fne
relat
chemotherapi
mean
number
fne
femal
male
patient
differ
number
fne
accord
gender
p
median
neutrophil
count
mm
median
crp
level
mgdl
normal
rang
pathogen
detect
fne
fne
one
microorgan
isol
fne
one
microorgan
isol
isol
microorgan
present
tabl
isol
bacteri
microorgan
gram
neg
bacteria
gram
posit
bacteria
among
tabl
although
number
fne
increas
autumn
signific
differ
frequenc
fne
month
p
season
p
fig
observ
fne
treat
singl
antibacteri
therapi
fne
treat
combin
antibacteri
treatment
antifung
treatment
ad
antibacteri
treatment
fne
antivir
treatment
appli
fne
manag
differ
accord
particular
season
twentyseven
fne
result
death
main
caus
death
sepsi
intracrani
bleed
acut
respiratori
distress
origin
report
discuss
today
variou
cytotox
antineoplast
therapi
wide
use
hematolog
cancer
howev
increas
frequenc
infect
due
myelosuppress
immunosuppress
caus
diseas
current
treatment
studi
show
lifethreaten
infect
occur
fen
patient
season
pattern
infect
observ
virus
caus
common
cold
temper
region
northern
hemispher
frequenc
respiratori
infect
increas
rapidli
autumn
remain
fairli
high
throughout
winter
decreas
spring
tropic
area
cold
aris
raini
season
base
presenc
season
viral
infect
pattern
studi
investig
whether
similar
season
chang
fne
found
differ
frequenc
fne
accord
month
season
probabl
reason
differ
accord
month
season
pathogen
larg
caus
endogen
flora
second
aim
studi
determin
type
frequenc
pathogen
detect
fne
patient
hematolog
cancer
proport
gram
neg
bacteria
significantli
higher
approxim
twice
much
ratio
gram
posit
bacteria
among
pathogen
e
coli
common
also
pathogen
show
chang
accord
season
therefor
empir
antimicrobi
therapi
requir
chang
accord
season
fen
medic
emerg
empir
treatment
start
soon
possibl
aim
empir
therapi
cover
like
virul
pathogen
may
rapidli
caus
lifethreaten
infect
therefor
clinician
need
awar
current
microbiolog
surveil
data
institut
vari
wide
center
center
allow
better
manag
process
select
appropri
empir
antimicrobi
therapi
limit
studi
followup
period
particip
suffici
studi
longer
followup
period
need
thoroughli
investig
season
frequenc
febril
neutropenia
wide
view
whole
world
practic
need
would
nice
know
frequenc
admiss
febril
episod
per
month
per
season
also
noncanc
patient
order
evalu
season
variat
infect
report
elsewher
also
observ
region
although
report
studi
region
said
viral
infect
common
autumn
winter
month
comprehens
studi
carri
presenc
noncanc
control
group
provid
clearer
inform
